Replimune Group, Inc. (REPL) - 10-Q Summary
Business Context and Reporting Period
Company: Replimune Group, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended December 31, 2025
Business Overview: Clinical-stage biotechnology company developing oncolytic immunotherapies (RPx platform) for cancer treatment. The company has no approved products and has not generated product revenue. Its lead candidate, RP1 (vusolimogene oderparepvec), is in Phase 2/3 trials for advanced melanoma and other skin cancers.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Dec 31, 2025 | 9 Months Ended Dec 31, 2025 | 9 Months Ended Dec 31, 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(70,930) | $(240,723) | $(173,167) |
| Loss Per Share (Basic/Diluted) | $(0.77) | $(2.62) | $(2.25) |
| Operating Expenses | $71,868 | $246,581 | $182,299 |
| Cash & Cash Equivalents | $122,951 | $269,137 (Total Liquidity incl. Short-term investments) | |
| Short-term Investments | $146,186 | ||
| Long-term Debt (Net) | $47,628 | $47,628 | |
| Accumulated Deficit | $(1,189,302) |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the nine months ended Dec 31, 2025, increased by $67.6 million compared to the prior year period, driven by higher R&D and SG&A expenses.
- R&D Expense Growth: R&D expenses rose $33.4 million year-over-year (9 months) to $168.9 million. This was primarily due to increased spending on the RP1 confirmatory study (IGNYTE-3) and RP2 enrollment, offset by decreases in the IGNYTE and CERPASS studies.
- SG&A Expense Growth: SG&A expenses increased $30.9 million year-over-year to $77.7 million, driven by personnel costs related to commercial infrastructure build-out and sales/marketing preparations for a potential RP1 launch.
- Investment Income Decline: Investment income decreased $4.0 million year-over-year due to lower average cash and investment balances.
- Debt Drawdown: In a subsequent event (January 2026), the company drew an additional $35.0 million tranche under its Hercules loan facility.
Guidance, Outlook, and Risks
- Regulatory Status (RP1): The FDA issued a Complete Response Letter (CRL) in July 2025 regarding the RP1 BLA. The company resubmitted the BLA in October 2025, which was accepted by the FDA with a new PDUFA date of April 10, 2026. Approval is not guaranteed.
- Liquidity Outlook: Management believes existing cash, short-term investments ($269.1 million as of Dec 31, 2025), plus the recent $35 million debt drawdown and ATM proceeds, will fund operations through late Q1 2027. This assumes potential commercialization of RP1 and excludes revenue.
- Legal Proceedings: The company is facing a class action lawsuit and derivative actions filed following the July 2025 CRL. Additionally, the SEC has opened an investigation regarding the RP1 BLA submission. No liability has been accrued as outcomes are uncertain.
- Internal Controls: The company identified material weaknesses in internal control over financial reporting related to IT general controls (change management, user access, etc.). Remediation is ongoing, but controls were deemed ineffective as of Dec 31, 2025.
- Stock-Based Compensation: Total stock-based compensation expense was $24.1 million for the nine months ended Dec 31, 2025.
Investor Verification Checklist
- RP1 Approval Probability: Verify the likelihood of FDA approval for the resubmitted BLA given the previous CRL and the April 2026 PDUFA date.
- Cash Runway: Confirm the burn rate and the sufficiency of the $269 million liquidity position to fund operations through Q1 2027 without further dilution or debt.
- Legal Exposure: Monitor the status of the SEC investigation and the class action lawsuit for potential financial impact or operational restrictions.
- Internal Control Remediation: Assess the progress of remediation efforts for the identified material weaknesses in IT general controls to ensure future financial reporting reliability.
- Debt Covenants: Review the terms of the Hercules Loan Agreement, specifically the financial covenants regarding unrestricted cash and market capitalization, to ensure compliance.